Position statements
A list of our position statements, outlining our recommendations and position on various topics
This position statement sets out our view on the use of AI methods in the generation and reporting of evidence considered by its evaluation programmes.
There are 2 different points of the lifecycle of a NICE Technology Appraisal at which consideration of reference to or inclusion of a biosimilar is appropriate. The procedure for each point is described in this position statement.
Biosimilar technologies: NICE position statement - information for the public
Our approach to biosimilar technologies.
NICE has been collaborating with NHS England on the Chemotherapy Dose Standardisation initiative which has been developed by the Medicines Optimisation and Chemotherapy Clinical Reference Groups (CRGs).
Position statement on use of the EQ-5D-5L value set for England (updated October 2019)
Our recommendations around the use of the EQ-5D-5L value set for England.
Patients taking part in clinical trials may receive drugs which have been evaluated by NICE technology appraisal guidance. Queries have been raised regarding the applicability of NICE technology appraisals for patients who have previously received the same medication as part of a clinical trial.
The UK Government is a signatory and party to the WHO Framework Convention on Tobacco Control (FCTC). As an Arm’s Length Body of Government, NICE has an obligation under Article 5.3 of the FCTC to protect public health policies from the commercial and other vested interests of the tobacco industry. This position statement sets out how NICE meets those obligations.